PAP
KPTI icon

Persistent Asset Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Persistent Asset Partners’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.11K Buy
+610
New +$4.65K ﹤0.01% 302

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Persistent Asset Partners's KPTI Position: Q1 2026 in Review

Persistent Asset Partners sold out of Karyopharm Therapeutics (KPTI) in Q1 2026, closing a stake of 18,316 shares — an estimated $140K sold.

Persistent Asset Partners first reported a position in KPTI in Q4 2025 and held it in 1 quarter. The position peaked at $135K in Q4 2025. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Persistent Asset Partners reported no remaining Karyopharm Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 18,316 Karyopharm Therapeutics shares in Q1 2026, an estimated $140K.
  • Persistent Asset Partners first reported a position in Karyopharm Therapeutics in Q4 2025 and held it in 1 quarter.
  • Persistent Asset Partners's Karyopharm Therapeutics position peaked at $135K in Q4 2025.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.